# Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

> **NCT03003494** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 306 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Spiolto® Respimat®

## Key facts

- **NCT ID:** NCT03003494
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-06
- **Primary completion:** 2018-07-30
- **Final completion:** 2018-07-30
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03003494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03003494, "Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03003494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*